Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade A 21.07 -2.36% -0.51
ACAD closed down 2.36 percent on Friday, January 18, 2019, on 1.18 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Jan 18 Slingshot Bullish Bullish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Wide Bands Range Expansion -2.36%
Jan 17 Overbought Stochastic Strength -2.36%
Jan 16 New Uptrend Bullish -3.22%
Jan 16 NR7 Range Contraction -3.22%
Jan 16 Wide Bands Range Expansion -3.22%
Jan 16 Overbought Stochastic Strength -3.22%
Jan 15 Pocket Pivot Bullish Swing Setup -1.22%

Older signals for ACAD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.99
52 Week Low 12.77
Average Volume 2,228,375
200-Day Moving Average 17.7319
50-Day Moving Average 18.4352
20-Day Moving Average 18.1065
10-Day Moving Average 20.471
Average True Range 1.1225
ADX 28.62
+DI 31.0114
-DI 14.2449
Chandelier Exit (Long, 3 ATRs ) 18.7525
Chandelier Exit (Short, 3 ATRs ) 17.3775
Upper Bollinger Band 23.2921
Lower Bollinger Band 12.9209
Percent B (%b) 0.79
BandWidth 57.278878
MACD Line 1.019
MACD Signal Line 0.5244
MACD Histogram 0.4946
Fundamentals Value
Market Cap 2.58 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -8.33
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.56
Resistance 3 (R3) 22.60 22.14 22.31
Resistance 2 (R2) 22.14 21.77 22.12 22.22
Resistance 1 (R1) 21.61 21.53 21.38 21.57 22.14
Pivot Point 21.15 21.15 21.04 21.13 21.15
Support 1 (S1) 20.62 20.78 20.39 20.58 20.00
Support 2 (S2) 20.16 20.54 20.14 19.92
Support 3 (S3) 19.63 20.16 19.83
Support 4 (S4) 19.59